Show simple item record

dc.contributor.authorPinto Paz, Mirian Elizabeth
dc.contributor.authorCotrina Concha, Jose Manuel
dc.contributor.authorBenites Zapata, Vicente A.
dc.date.accessioned2023-03-23T22:00:22Z
dc.date.available2023-03-23T22:00:22Z
dc.date.issued2021-01
dc.identifier.citationCancer Treatment and Research Communications. 2021;29.es_PE
dc.identifier.issn2468-2942
dc.identifier.urihttps://hdl.handle.net/20.500.12959/3509
dc.description.abstractIntroduction: Cutaneous malignant melanoma (CMM) incidence has risen rapidly in the last 50 years. Poor progression and high mortality characterize CMM, making a thorough understanding of progression and associated factors essential for optimizing care. Aims: We assessed the association between the Neutrophil-to-Lymphocyte Ratio (NLR) and mortality in adults with CMM from an entirely mixed-race Hispanic population during 12 consecutive years of extensive follow-up. Material & Methods: We performed a retrospective cohort study in a tertiary hospital in Peru. NLR was categorized with a cutoff value higher or equal than 3. We collected demographic variables, laboratory results and treatments at baseline of follow-up. Cox regression analysis was performed, and we calculated crude and adjusted hazard ratios (HR) and their 95% confidence interval (95%CI). Results: The analysis was from 615 CMM cases, and there were 378 deaths. Most melanomas (63.6%) were acral lentiginous. The crude analysis showed that high NLR is a risk factor for mortality, HR = 2.52; 95%CI (2.03–3.14). High NRL ratio remains statistically significant after adjusting for confounding variables, aHR = 1.61; 95%CI (1.16–2.24). Other risk factors for mortality were clinical stages III and IV, older than 60 years, females and greater Breslow thickness. Conclusions: We concluded that high NRL ratio is a risk factor for mortality and should be monitored in every patient who is diagnosed with malignant melanoma during their first blood count. It should then be carried out in follow-up controls for patients of clinical stage III and IV only, or in patients who present a relapse.es_PE
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherElsevieres_PE
dc.relation.urihttps://www.sciencedirect.com/science/article/pii/S246829422100160Xes_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/es_PE
dc.subjectCutaneous malignant melanomaes_PE
dc.subjectNeutrophil-lymphocyte ratioes_PE
dc.subjectPrognosises_PE
dc.subjectProgressiones_PE
dc.subjectMelanoma maligno cutáneoes_PE
dc.subjectRelación neutrófilos-linfocitoses_PE
dc.titleMortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratioes_PE
dc.title.alternativeMortalidad en melanoma maligno cutáneo y su asociación con la relación neutrófilos a linfocitoses_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.21es_PE
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.15es_PE
dc.identifier.doihttps://doi.org/10.1016/j.ctarc.2021.100464


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

El repositorio recopila la documentación y publicaciones institucionales, producto de la investigación y el desempeño en defensa de la competencia, la propiedad intelectual y protección al consumidor, para su difusión en el entorno social y académico. Se difunde en acceso abierto y está alineado con las Declaraciones de Budapest y de Berlín.

Contactos